In hematologic malignancies CCL3 is a well-known mechanism of BMME disruption in multiple myeloma, both activating osteoclastic bone resorption, and inhibiting bone forming osteoblastic cells6. This evidence concerns the gene CCL3 and plasma cell myeloma.